CZR heads into September in a peculiar limbo: a $31-per-share takeout bid from Fertitta Entertainment sits on the table, yet the stock trades at $29.67 — a discount that tells you the market is still pricing in deal risk rather than deal certainty.
The short side reflects that same hesitation. Short interest climbed roughly 3.7% across the week to 9.1% of the free float, reversing a broader monthly decline and pushing the ORTEX short score to 49.1 — its highest reading in the ten-day window available. The weekly increase is modest in absolute terms, but the direction matters: shorts had been unwinding through July, and that unwind stalled abruptly once the stock failed to close the gap to the bid price. Borrowing costs remain inconsequential at 0.35%, and availability is essentially unlimited at over 4,700% — plenty of room for the short base to grow further without any squeeze pressure in the lending market. The options market adds a mild layer of caution: the put/call ratio of 0.37 runs above its 20-day average of 0.33, about 1.2 standard deviations elevated, though still well off any extreme reading.
The Street has moved decisively to the sidelines since the deal was announced. The analyst consensus now shows zero buy ratings across 14 analysts, all clustered at hold, with price targets converging tightly around $31 — essentially ratifying the bid price rather than underwriting the standalone business. TD Cowen downgraded from Buy to Hold on July 29, the most recent bellwether move, while Barclays dropped its Overweight rating on July 9, cutting the target from $35 to $31 in one step. The bull case at this point is less about fundamental improvement and more about deal optionality: the go-shop period that ran through July 11 could yet surface a competing bid, and the transaction price implies roughly 7.5x 2026 EV/EBITDA — a multiple some see as leaving room for a counteroffer in a consolidating regional gaming market. The bear case is simpler: CZR carries roughly $11.9 billion of assumed debt, the quant factors are weak on profitability and value, and if the deal closes as structured, the upside from here is the spread to $31, not a fundamental re-rating.
The ownership register adds one notable wrinkle. Pentwater Capital Management filed a fresh Schedule 13G in mid-August, disclosing a 5.6% stake of 11.5 million shares — a position built almost entirely in the second quarter, when last reported data shows an 8.8 million share increase. Pentwater is a firm with a history of merger arbitrage and event-driven positioning, and its sudden appearance at 5.6% is a signal that at least one sizeable holder is playing the deal spread rather than the business. BlackRock simultaneously lifted its holding to 13.5% as of July 31, adding roughly 2.1 million shares. As with all Schedule 13D/G data, these stakes reflect positions as last disclosed around the 5% threshold — holders who move below that level are not required to update. Capital World Investors, which previously held 7.8% of the company, had already exited to a negligible position by mid-August.
The most recent earnings print — released July 28 — sent the stock down just 0.7% on the day, with a partial recovery of 0.5% over the following five sessions. That muted reaction is consistent with an investor base that has largely stopped trading the fundamentals and is focused almost entirely on whether the $31 deal price holds, whether a competing bid materialises before close, or whether the debt-heavy capital structure causes any last-minute friction.
With no further earnings expected until November 3, the next material data point for CZR is regulatory progress on the Fertitta transaction — and whether the spread between $29.67 and the $31 bid narrows or widens from here will likely say more about deal confidence than anything the company reports.
See the live data behind this article on ORTEX.
Open CZR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
